ClinicalTrials.gg
RecruitingNCT07769489RISEUpdated Sep 15, 2026

Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance

A Phase 1 interventional study of Syringe Pump in Healthy Participants, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The purpose of the study is to investigate the tolerability of different injection/infusion volumes and speed compared to standard practise. The order in which the different volumes and injection speeds will be given to participants will be allocated by chance. Participants will be in this clinical study for about 1 week.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Healthy male or female participants as judged by the investigator.
  • Age 18-64 years (both inclusive) at the time of signing the informed consent.
  • (BMI) greater than or equal to (>=) 18.5 and less than or equal to (\<=) 30.0 kilograms per square metre (kg/m\^2) (both included).
  • White (Light skin that allows for adequate medical evaluation of any skin reactions).

Exclusion criteria

Exclusion criteria:

  • Known or suspected to study intervention(s) or related products.
  • Previous randomisation in this study.
  • Previous rescreening for this study.
  • Pregnant or breastfeeding female participants.
  • Current participation (i.e., signed ) in any other interventional clinical study. Treatment with an medical product within 3 months or 5 half-lives (if known), whichever is longer prior to screening.
  • Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol, including insufficient abdominal area for injection.
  • Intake of any medication that could influence pain perception or injection site reaction appearance (e.g., anti-coagulants, including low dose of aspirin, systemic antihistamines, pain-relieving, or anti-inflammatory medicinal products) within the last week before the intervention.
  • Intake of alcohol within the last 24 hours (self-reported) or a positive result of alcohol breath test prior to randomisation and intervention.
  • Intake of illicit drugs within the last 48 hours (self-reported) or a positive result of urine drug screening prior to screening.
  • Use of any nicotine products within the past month before screening.
  • Known active or inactive skin condition or disease, tattoos, or other interventions in the injection area that may affect pain perception or assessment of injection-site reactions.
  • Strenuous exercise within 3 days prior to the intervention.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Pilot cohort

    Participants will receive subcutaneous injections and infusions of sodium chloride (NaCl) solution in varying combinations of speed and volume at different abdominal sites in a randomised sequence. A syringe pump with an attached syringe will be used for delivery of subcutaneous injections and infusions.

    Device: Syringe Pump

  • Experimental
    Main cohort

    Participants will receive subcutaneous injections and infusions of sodium chloride (NaCl) solution in varying combinations of speed and volume (that have passed safety assessment in pilot cohort) at different abdominal sites in a randomised sequence. A syringe pump with an attached syringe will be used for delivery of subcutaneous injections and infusions.

    Device: Syringe Pump

Interventions

  • DeviceSyringe Pump

    Device used for delivery of subcutaneous injections and infusions of NaCl solution.

06

What researchers measure

Primary outcomes

  1. Injection pain rated on a Visual Analogue Scale (VAS)

    The VAS scale consists of a 100 mm line on a paper where 1 will be no pain and 100 being the worst pain imaginable. The VAS response will be recorded in millimetres (mm).

    Time frame: 1 minute (±1 minute) from the injection initiation

  2. Injection pain rated on a VAS

    The VAS scale consists of a 100 mm line on a paper where 1 will be no pain and 100 being the worst pain imaginable. The VAS response will be recorded in mm.

    Time frame: 9 minutes (±1minute) from the injection initiation

Secondary outcomes

  1. Acceptance of pain for each injection (including the needle insertions only) as a binary measure

    Measured as binary response (Acceptable/Not acceptable).

    Time frame: 1 minute (±1 minute) from the injection initiation

  2. Back flow at the injection site

    Measured in microlitres (μL).

    Time frame: 5 minutes (±1 minute) from the injection initiation

  3. Number of acute injection site reactions (haematoma, haemorrhage, bruising, erythema and oedema formation) after each injection

    Measured in injection site reactions (events).

    Time frame: 9 minutes (±1 minute) from the injection initiation

  4. Number of long term injection site reactions (haematoma, haemorrhage, bruising, erythema and oedema formation)

    Measured in injection site reactions (events).

    Time frame: 16-40 hours after all injections with an additional 36 hours if a clinic visit is needed

  5. Number of adverse events

    Measured in events.

    Time frame: Up to 40 hours after completing all the injections with an additional 36 hours if a clinic visit is needed

07

Study locations

1 of 1 sites recruiting
  • Novo Nordisk Clinical Innovation Centre A/S
    Gentofte Municipality, 2820, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 18, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Dec 9, 2026
CompletionEst.
Dec 11, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07769489
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 18, 2026
Start date
Aug 17, 2026
Primary completion
Dec 9, 2026 (estimated)
Completion
Dec 11, 2026 (estimated)
Last update
Sep 15, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion